Strategic Collaboration Between Pillar Biosciences and Hamilton Company
The partnership between Pillar Biosciences, recognized for its innovations in Decision Medicine™, and Hamilton Company marks a significant advancement in the field of next-generation sequencing (NGS) testing. By joining forces, these two leaders aim to streamline the automation processes associated with NGS, fostering better testing outcomes for clinical environments.
Enhancing NGS Automation
Under the newly formed agreement, Hamilton Company is set to develop automation scripts along with essential technical and marketing materials for select research-use-only NGS panels offered by Pillar Biosciences. These will be integrated into Hamilton's top-tier Microlab® STAR Liquid Handling Systems, which are renowned for their efficiency and precision.
First Steps Toward Improved Testing
The initial focus will be on developing an automation script for Pillar's oncoReveal® Essential MPN panel. This panel is crucial in the cancer testing landscape, facilitating comprehensive tumor profiling and aiding in therapy decision-making processes. By maximizing automation, both companies aspire to mitigate traditional barriers like workflow complexity and cost, ultimately making NGS testing more accessible.
Benefits for Laboratories and Clinicians
Dan Harma, Chief Commercial Officer of Pillar Biosciences, highlighted the pressing need for faster and more cost-effective testing solutions. He emphasized that the integration of Pillar's robust NGS products with Hamilton's automation capabilities will not only expedite results but also lower operational costs for laboratories.
Excitement About the Partnership
Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton Company, expressed enthusiasm for the collaborative venture. He noted that the amalgamation of Pillar's cutting-edge technologies with Hamilton's proven systems offers an unparalleled opportunity to improve NGS testing across the board.
Global Reach of the Agreement
This pivotal agreement initially targets multiple regions, spanning North America, Central and South America, New Zealand, and various countries in the Asia-Pacific (APAC) area. This broad geographical focus reflects the commitment of both companies to expand the accessibility of NGS testing solutions internationally.
About Pillar Biosciences
Pillar Biosciences is a leader in utilizing highly accurate NGS testing technology, enhancing the precision of therapy selection for cancer patients. Their innovative products leverage advanced technologies like SLIMamp® and PiVAT®, aiming to reduce diagnostic costs and improve access to critical testing.
About Hamilton Company
Hamilton Company stands as a global powerhouse in liquid handling and automated solutions, boasting over 60 years of excellence in the industry. With a steadfast commitment to quality and precision, Hamilton has garnered ISO 9001 Certification and maintains a strong reputation internationally.
Frequently Asked Questions
What is the main purpose of the partnership?
The partnership aims to enhance automation in NGS testing, making it more efficient and accessible for laboratories and clinical settings.
Which product is highlighted in this partnership?
The focus is on Pillar's oncoReveal® Essential MPN panel, crucial for tumor profiling in cancer patients.
What regions are covered under this agreement?
The initial agreement covers North America, Central and South America, New Zealand, and several APAC countries.
What technologies does Pillar Biosciences utilize?
Pillar employs technologies like SLIMamp® and PiVAT® to optimize NGS testing processes and improve diagnostic efficiency.
How has Hamilton Company established its reputation?
Hamilton has a legacy of over 60 years in design and manufacturing of liquid handling solutions, earning global recognition for quality and precision.
